← Amneal Pharmaceuticals, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net revenue | $1.0b | $1.7b | $1.6b | $2.0b | $2.1b | $2.2b | $2.4b | $2.8b | $3.0b | $3.1b | |
| Cost of goods sold | $507.5m |
$938.8m
+84.99%
|
$1.1b
+22.20%
|
$1.3b
+15.89%
|
$1.3b
-2.07%
|
$1.4b
+8.79%
|
$1.6b
+11.05%
|
$1.8b
+12.74%
|
$1.9b
+7.44%
|
$1.9b
-0.72%
|
|
| Gross profit | $526.2m |
$716.4m
+36.15%
|
$353.0m
-50.73%
|
$628.4m
+78.02%
|
$769.0m
+22.37%
|
$784.7m
+2.05%
|
$820.6m
+4.57%
|
$1.0b
+24.36%
|
$1.1b
+9.10%
|
$1.2b
+10.10%
|
|
| Research and development | $171.4m | $194.2m | $188.0m | $179.9m | $201.8m | $195.7m | $163.9m | $190.7m | $186.2m | $183.0m | |
| In-process research and development impairment charges | $0 | $39.3m | $46.6m | $2.7m | $710k | $13.0m | $30.8m | $0 | $0 | — | |
| Selling, general and administrative | $109.0m | $227.8m | $289.6m | $326.7m | $365.5m | $399.7m | $429.7m | $476.4m | $526.8m | $571.9m | |
| Restructuring and other charges | $0 | $56.4m | $34.3m | $2.4m | $1.9m | $1.4m | $1.7m | $2.4m | $4.2m | — | |
| Other operating income | — | ($19.7m) | ($248.7m) | $0 | $0 | ($4.0m) | ($1.1m) | $0 | ($5.2m) | — | |
| Operating income | $245.1m |
($19.7m)
-108.03%
|
($248.7m)
-1164.08%
|
$91.2m
+136.66%
|
$152.7m
+67.53%
|
($94.9m)
-162.16%
|
$204.4m
+315.29%
|
$249.3m
+21.99%
|
$394.1m
+58.06%
|
$479.2m
+21.60%
|
|
| Interest expense, net | ($71.1m) | ($143.6m) | ($168.2m) | ($146.0m) | ($136.3m) | ($158.4m) | ($210.6m) | ($258.6m) | ($241.1m) | $227.5m | |
| Foreign exchange gain (loss), net | $29.1m | ($19.7m) | ($5.0m) | $16.4m | ($355k) | ($12.4m) | $1.7m | ($6.8m) | $7.6m | — | |
| Other income, net | ($47k) | $1.2m | $1.5m | $2.6m | $15.3m | $17.8m | $5.1m | $11.8m | $16.5m | ($15.7m) | |
| Total other expense, net | ($73.8m) | ($183.0m) | $28.4m | ($126.9m) | ($121.3m) | ($153.2m) | ($244.6m) | ($304.3m) | ($254.9m) | — | |
| Income (loss) before income taxes | $171.3m | ($202.7m) | ($220.2m) | ($35.8m) | $31.4m | ($248.1m) | ($40.3m) | ($55.0m) | $139.2m | — | |
| Provision for income taxes | $2.0m | ($1.4m) | $383.3m | ($104.4m) | $11.2m | $6.7m | $8.5m | $18.9m | $11.3m | — | |
| Net income (loss) | $169.3m |
($201.3m)
-218.89%
|
($603.6m)
-199.83%
|
$68.6m
+111.36%
|
$20.2m
-70.59%
|
($254.8m)
-1363.21%
|
($48.7m)
+80.88%
|
($73.9m)
-51.63%
|
$127.9m
+273.17%
|
$157.4m
+23.00%
|
|
| Less: Net income attributable to non-controlling interests | ($1.7m) | $32.8m | $241.7m | $22.5m | ($9.5m) | $125.2m | ($35.3m) | ($43.0m) | ($55.9m) | — | |
| Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | $0 | ($19.7m) | ($361.9m) | $91.1m | $10.6m | ($130.0m) | ($84.0m) | ($116.9m) | $72.1m | $157.4m | |
| Basic (in dollars per share) | — | ($0.16) | ($2.74) | $0.62 | $0.07 | ($1.69) | ($0.28) | ($0.24) | $0.41 | — | |
| Diluted (in dollars per share) | — | ($0.16) | ($2.74) | $0.61 | $0.07 | ($1.69) | ($0.28) | ($0.24) | $0.39 | — | |
| Intellectual property legal development expenses | $20.5m | $16.3m | $14.2m | $10.7m | $7.7m | $4.4m | $3.8m | $5.8m | $7.6m | — | |
| (Credit) charges related to legal matters, net | ($29.3m) | ($19.7m) | $12.4m | $5.9m | $25.0m | $269.9m | $1.8m | $96.7m | ($390k) | — | |
| Loss on refinancing | ($2.5m) | ($19.7m) | $0 | $0 | $0 | ($291k) | ($40.8m) | $0 | ($31.4m) | — | |
| Increase in tax receivable agreement liability | — | — | — | — | — | ($631k) | ($3.1m) | ($50.7m) | ($6.6m) | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.